Old Web
English
Sign In
Acemap
>
Paper
>
FRI0276 TIME OF DISEASE EVOLUTION AND EFFICACY OF TOCILIZUMAB IN GIANT CELL ARTERITIS
FRI0276 TIME OF DISEASE EVOLUTION AND EFFICACY OF TOCILIZUMAB IN GIANT CELL ARTERITIS
2019
Mónica Calderon-Goercke
Javier Loricera
Diana Prieto Peña
Vicente Aldasoro
Santos Castañeda
Ignacio Villa-Blanco
Alicia Humbría
Clara Moriano
Susana Romero-Yuste
Javier Narváez
Catalina Gómez Arango
Eva Perez-Pampin
Rafael Melero
Elena Becerra Fernández
Marcelino Revenga
Noelia Álvarez Rivas
Carles Galisteo
Francisca Sivera
Alejandro Olivé
María Álvarez del Buergo
Luisa Marena-Rojas
Carlos Fernández López
Francisco Navarro
Enrique Raya
Eva Galíndez
Beatriz Arca
Roser Solans-Laqué
Arantxa Conesa
Cristina Hidalgo
Carlos Vázquez
José Andrés Román Ivorra
Pau Lluch
Sara Manrique Arija
Paloma Vela Casasempere
Eugenio de Miguel
Carmen Torres-Martín
Juan Carlos Nieto
Carmen Ordás Calvo
Eva Salgado Pérez
Cristina Luna Gómez
J Francisco
Toyos Sáenz de Miera
N. Fernández-Llanio
Antonio G. García
Carmen Larena
Natalia Palmou-Fontana
Vanesa Calvo-Río
Carmen González Vela
Alfonso Corrales
María Varela-García
Elena Aurrecoechea
Raquel dos Santos
Ángel García Manzanares
Norberto Ortego
Sabela Fernández
Francisco Ortiz-Sanjuán
Montserrat Corteguera
J. Luis Hernandez
Miguel A. González-Gay
Ricardo Blanco
Keywords:
Disease
Physical therapy
Medicine
Diabetes mellitus
Tocilizumab
Giant cell arteritis
Gastroenterology
Internal medicine
disease evolution
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]